Genea Biomedx partnered its three fertility products in development with Merck KGaA last month. Now it’s won a CE mark for two of them: the Gavi automated vitrification instrument and the Geri benchtop incubator.
Under the May deal, Merck not only gains global marketing and commercialization rights to all three products, the third being the embryo culture media known as Gems, but it also gains rights to all future pipeline products that it plans to develop in partnership with Genea Biomedx. The financial terms of that deal are undisclosed.
Earlier this month, Merck also disclosed collaboration dubbed the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment. Along with Merck and Genea Biomedx, high-profile genetic analysis company Illumina ($ILMN) is also a partner in this collaboration. The idea behind the alliance is to help standardize the technologies and protocols used in assisted reproductive technology (ART) laboratories, which vary widely between countries and even within them.